New hope for Platinum-Resistant ovarian cancer?
NCT ID NCT07278336
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an investigational drug called ABBV-901, alone or with a standard drug bevacizumab, in about 219 adults with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if the drug can shrink tumors. Participants will receive the drug through an IV and will be closely monitored with frequent tests and scans over about 3 years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABBV-901 (an investigational drug) and bevacizumab (a standard cancer therapy)
What this could lead to
If successful, this could point toward a new treatment option for ovarian cancer that is resistant to platinum-based therapies.
What could go wrong
This is an early Phase 1 trial, so safety and effectiveness are not yet proven. The drug may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Cancer Hospital /ID# 282600
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Hadassah Medical Center-Hebrew University /ID# 278420
RECRUITINGJerusalem, 91120, Israel
-
NEXT Oncology - San Antonio /ID# 278606
RECRUITINGSan Antonio, Texas, 78229, United States
-
National Cancer Center Hospital East /ID# 278604
RECRUITINGKashiwa-shi, Chiba, 277-8577, Japan
-
New Zealand Clinical Research (Christchurch) /ID# 281467
NOT_YET_RECRUITINGChristchurch, Canterbury, 8011, New Zealand
-
Next Virginia /ID# 278607
RECRUITINGFairfax, Virginia, 22031, United States
-
Qilu Hospital Of Shandong University /ID# 283564
NOT_YET_RECRUITINGJinan, Shandong, 250014, China
-
Rambam Health Care Campus /ID# 278418
RECRUITINGHaifa, 3109601, Israel
-
Saitama Medical University International Medical Center /ID# 278437
RECRUITINGHidaka, Saitama, 350-1298, Japan
-
Sarah Cannon Research Institute at HealthONE /ID# 278785
RECRUITINGDenver, Colorado, 80218, United States
-
Shandong Cancer Hospital /ID# 283566
NOT_YET_RECRUITINGJinan, Shandong, 250117, China
-
Shizuoka Cancer Center /ID# 278538
RECRUITINGSunto-gun, Shizuoka, 411-8777, Japan
-
Start Mountain Region /ID# 278609
RECRUITINGWest Valley City, Utah, 84119, United States
-
Sun Yat-Sen University Cancer Center /ID# 282505
NOT_YET_RECRUITINGGuangzhou, Guangdong, 510060, China
-
The Chaim Sheba Medical Center /ID# 278416
RECRUITINGRamat Gan, Tel Aviv, 5265601, Israel
-
University of Chicago Medical Center /ID# 278295
RECRUITINGChicago, Illinois, 60637, United States